Archive · 12 Aug 2025
FDA Approves Iron Sucrose Generics; Indian Firms Face Competition
The FDA has approved generic versions of Iron Sucrose, a drug with significant sales in the US.
This means more companies can now sell it.
The approval went to Viatris and Amphastar.
Citi analysts suggest they might get extra time to sell their version exclusively.
Previously, companies like Dr. Reddy’s and Aurobindo Pharma were looking at this drug as a major product for their business.
However, with the recent approvals, it could become harder for them to compete, potentially impacting their market share.
The FDA approved generic versions of Iron Sucrose from Viatris and Amphastar.
Citi analysts noted the potential for 180 days of Competitive Generic Therapy (CGT) exclusivity.
No Indian pharmaceutical companies have announced FDA clearance for the product.
Dr. Reddy's Laboratories and Aurobindo Pharma had considered Iron Sucrose a key pipeline product.
Intensified competition could reduce or eliminate the market opportunity for Indian players.
- Who
- Viatris and Amphastar received FDA approval.
- What
- The FDA approved generic versions of Iron Sucrose.
- When
- Over the past 12 months, Iron Sucrose recorded US sales of $512 million.
- Where
- United States
- Why
- To provide more competition in the market for Iron Sucrose.
Indian Pharmaceutical Companies
Viatris and Amphastar
Market Competition
Indian Pharmaceutical Companies
Dr. Reddy’s and Aurobindo Pharma expected the product to be a key product.
Viatris and Amphastar
Viatris and Amphastar have gained FDA approval.
- Drug Name
- Iron Sucrose
- Approved Companies
- Viatris and Amphastar
- Potential Exclusivity
- 180 days CGT
- Targeted Companies
- Dr. Reddy’s and Aurobindo Pharma
- Recent US Sales
- $512 million